These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 11553266)

  • 1. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.
    Kawatani T; Suou T; Tajima F; Ishiga K; Omura H; Endo A; Ohmura H; Ikuta Y; Idobe Y; Kawasaki H
    Eur J Haematol; 2001 Jul; 67(1):45-50. PubMed ID: 11553266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
    World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
    Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies.
    El-Sayed MH; Mohamed MM; Karim A; Maina AM; Oliveri F; Brunetto MR; Bonino F
    Hematol J; 2003; 4(5):321-7. PubMed ID: 14502256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
    Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
    Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection.
    Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Bartolomé J; Pardo M; Carreño V
    J Med Virol; 2007 Mar; 79(3):236-41. PubMed ID: 17245725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation.
    Locasciulli A; Bruno B; Alessandrino EP; Meloni G; Arcese W; Bandini G; Cassibba V; Rotoli B; Morra E; Majolino I; Alberti A; Bacigalupo A;
    Bone Marrow Transplant; 2003 Feb; 31(4):295-300. PubMed ID: 12621466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies.
    Said ZN; El-Sayed MH; El-Bishbishi IA; El-Fouhil DF; Abdel-Rheem SE; El-Abedin MZ; Salama II
    Liver Int; 2009 Apr; 29(4):518-24. PubMed ID: 19192168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study.
    Wang Y; Luo XM; Yang D; Zhang J; Zhuo HY; Zhang J; Jiang Y
    World J Gastroenterol; 2013 Feb; 19(6):923-30. PubMed ID: 23429298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of hepatitis B and C virus infection on graft function after renal transplantation.
    Behzad-Behbahani A; Mojiri A; Tabei SZ; Farhadi-Andarabi A; Pouransari R; Yaghobi R; Rahsaz M; Banihashemi M; Malek-Hosseini SA; Javid A; Bahador A; Reisjalali A; Behzadi S; Salehipour M; Salahl A; Davari R; Janghorban P; Torb A; Salah AR
    Transplant Proc; 2005 Sep; 37(7):3045-7. PubMed ID: 16213299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
    Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
    J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
    Belperio PS; Shahoumian TA; Mole LA; Backus LI
    Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of patients with dual infection by hepatitis B and C viruses.
    Zarski JP; Bohn B; Bastie A; Pawlotsky JM; Baud M; Bost-Bezeaux F; Tran van Nhieu J; Seigneurin JM; Buffet C; Dhumeaux D
    J Hepatol; 1998 Jan; 28(1):27-33. PubMed ID: 9537860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization.
    Sung PS; Bae SH; Jang JW; Song DS; Kim HY; Yoo SH; Park CH; Kwon JH; Song MJ; You CR; Choi JY; Yoon SK
    Korean J Hepatol; 2011 Dec; 17(4):299-306. PubMed ID: 22310794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational use of polymerase chain reaction--based detection of viral genomes in patients with serologic markers of hepatitis B or C virus infection.
    Pfeffel F; Oesterreicher C; Penner E; Ferenci P; Sillaber C; Fiedler R; Müller C
    Wien Klin Wochenschr; 1997 Jan; 109(1):20-4. PubMed ID: 9037744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy.
    Francisci D; Falcinelli F; Schiaroli E; Capponi M; Belfiori B; Flenghi L; Baldelli F
    Infection; 2010 Feb; 38(1):58-61. PubMed ID: 19904491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.